8-K: Disc Medicine Q2 2025 Results & Pipeline Update

Disc Medicine reports Q2 2025 financial results and provides key updates on its clinical pipeline, including progress towards an NDA submission for bitopertin and advancements in DISC-0974 and DISC-3405 programs.

Summary

• Reported financial results for the second quarter ended June 30, 2025.
• On track to submit a New Drug Application (NDA) for bitopertin in erythropoietic protoporphyria (EPP) under the accelerated approval pathway in October 2025, following a successful pre-NDA meeting.
• Expect initial data from the Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) in Q4 2025.
• Expect multiple dose data from the Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025.
• Initiated a Phase 2 study of DISC-3405 in polycythemia vera (PV), with initial data expected in 2026.
• Ended Q2 2025 with a strong financial position, holding $650.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028.
• Research and Development (R&D) expenses increased to $46.3 million for Q2 2025, compared to $23.5 million for Q2 2024.
• Selling, General and Administrative (SG&A) expenses increased to $15.1 million for Q2 2025, compared to $7.4 million for Q2 2024.
• Net loss for Q2 2025 was $55.2 million, compared to $26.4 million for Q2 2024.

Sentiment

Score: 7

Explanation: While financial losses increased due to pipeline advancement, the significant clinical progress, especially the bitopertin NDA timeline and strong cash runway, indicates positive operational momentum and future potential.

Positives

• On track to submit NDA for bitopertin in EPP under accelerated approval pathway in October 2025, supported by successful pre-NDA meeting.
• Presented positive clinical data updates across the portfolio at the European Hematology Association (EHA) Annual Congress, including longer-term efficacy and safety data from the HELIOS trial of bitopertin in EPP, durability data from Phase 1b study of DISC-0974 in MF anemia, and healthy volunteer data from DISC-3405 studies.
• Strong financial position ending Q2 2025 with $650.0 million in cash, cash equivalents, and marketable securities.
• Cash runway expected to fund operations into 2028.
• Initiated Phase 2 study of DISC-3405 in polycythemia vera (PV).
• Publication of preclinical study results for bitopertin showing potential to prevent liver disease in EPP, in addition to ameliorating blood PPIX levels.
• Appointed Nadim Ahmed, President and CEO of Cullinan Therapeutics, to the Board of Directors in July, bringing over 25 years of development and commercial leadership experience.

Negatives

• Net loss increased to $55.2 million for the three months ended June 30, 2025, compared to $26.4 million for the same period in 2024.
• Research and Development expenses increased to $46.3 million for Q2 2025, up from $23.5 million in Q2 2024, primarily due to portfolio progression and a $10 million milestone payment.
• Selling, General and Administrative expenses increased to $15.1 million for Q2 2025, up from $7.4 million in Q2 2024, primarily due to increased headcount and infrastructure for potential commercialization.

Risks

• The adequacy of capital to support future operations and the ability to successfully initiate and complete clinical trials.
• Difficulty in predicting the time and cost of development of product candidates.
• The timing of initiation of planned preclinical studies and clinical trials.
• The timing of the availability of data from clinical trials.
• The ability to identify additional product candidates with significant commercial potential and to expand the pipeline in hematological diseases.
• The risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval.
• New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

Future Outlook

The company is on track to submit an NDA for bitopertin in EPP under the accelerated approval pathway in October 2025. Initial data from the Phase 2 study of DISC-0974 in MF anemia and multiple dose data from the Phase 1b study of DISC-0974 in NDD-CKD anemia are expected in Q4 2025. Initial data from the Phase 2 study of DISC-3405 in PV is expected in 2026. The strong financial position is expected to fund operations into 2028.

Management Comments

• "We are pleased with the continued momentum this past quarter, highlighted by clinical data presentations that support further advancement across our programs and continued progress toward our first NDA submission."
• "Following positive feedback from our pre-NDA meeting, we are on track to submit an NDA for bitopertin in EPP under the accelerated approval pathway in October."
• "We have also made great progress across the rest of our pipeline, initiating a Phase 2 study of DISC-3405 in polycythemia vera, and looking ahead to data from the Phase 2 trial of DISC-0974 in MF anemia and Phase 1b trial in NDD-CKD anemia in the second half of the year."
• "Our teams commitment to execution, supported by a strong balance sheet that provides cash runway into 2028, has positioned Disc to prepare for the potential commercialization of bitopertin and advance pipeline development as we enter the next phase of growth."

Industry Context

Disc Medicine operates in the clinical-stage biopharmaceutical sector, specifically targeting serious hematologic diseases by modulating heme biosynthesis and iron homeostasis. The progress with bitopertin towards an accelerated approval NDA submission positions the company to potentially bring a novel treatment to market for EPP, a rare disease, aligning with industry trends of developing targeted therapies for unmet medical needs. The advancement of other pipeline candidates (DISC-0974, DISC-3405) for anemia of myelofibrosis, NDD-CKD, and polycythemia vera indicates a broad approach within hematology, addressing conditions with significant patient populations and ongoing therapeutic needs.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to pipeline advancement, especially bitopertin's NDA submission and strong cash runway. Increased net loss and expenses could be a short-term concern.
• Patients: Potential for new treatments for serious hematologic diseases like EPP, MF anemia, NDD-CKD anemia, and PV.
• Employees: Increased headcount noted, indicating growth and potential for new opportunities.
• Creditors/Suppliers: Stable financial position with significant cash reserves suggests low credit risk.

Next Steps

• Submit NDA for bitopertin in EPP under accelerated approval pathway in October 2025.
• Continue progressing confirmatory Phase 3 APOLLO clinical trial of bitopertin in adults and adolescents with EPP.
• Expect initial data from Phase 2 study of DISC-0974 in patients with anemia of MF in Q4 2025.
• Expect multiple dose data from Phase 1b study of DISC-0974 in patients with anemia of NDD-CKD in Q4 2025.
• Expect initial data from Phase 2 study of DISC-3405 in PV in 2026.
• Prepare for potential commercialization of bitopertin.
• Advance pipeline development.

Key Dates

Recommendation

The company is making significant clinical progress, particularly with bitopertin nearing an NDA submission under accelerated approval, which is a major positive catalyst. The strong cash position provides a long runway into 2028, reducing immediate financing concerns. However, the substantial increase in net loss and operating expenses reflects the high cost of drug development. While these expenses are necessary for pipeline advancement, they contribute to a negative earnings profile. Investors should hold to observe the outcome of the bitopertin NDA and the upcoming data readouts for DISC-0974 and DISC-3405, as these events will be critical in determining the company's future valuation and commercial prospects.

Keywords

Biopharmaceutical, Hematologic Diseases, Clinical-stage, Bitopertin, DISC-0974, DISC-3405, Erythropoietic Protoporphyria (EPP), Myelofibrosis (MF) Anemia, Chronic Kidney Disease (CKD) Anemia, Polycythemia Vera (PV), NDA Submission, Accelerated Approval, Clinical Trials, Drug Development, Iron Homeostasis, Heme Synthesis